Top 3 Health Care Stocks That Are Preparing To Pump In Q4

Several healthcare sector stocks, including MoonLake Immunotherapeutics (MLTX), CorVel Corp (CRVL), and Harmony Biosciences (HRMY), are currently identified as oversold with RSI values below 30, potentially signaling buying opportunities. MLTX experienced an 86% monthly decline following Phase 3 trial results, CRVL fell 14% after a CFO resignation, and HRMY dropped 24% post-Phase 3 data, despite its CEO emphasizing a strong, profitable pipeline.

Analysis

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of major oversold players in this sector, having an RSI near or below 30. MoonLake Immunotherapeutics (NASDAQ:MLTX) - On Sept. 28, MoonLake Immunotherapeutics reported week-16 results from its Phase 3 VELA-1 and VELA-2 trials. The trials used HiSCR75—a 75% reduction in abscess and inflammatory nodule count with no increase in abscesses or draining tunnels—as the primary endpoint. The company's stock fell around 86% over the past month and has a 52-week low of $5.95. - RSI Value: 21.5 - MLTX Price Action: Shares of MoonLake Immunotherapeutics jumped 13% to close at $8.43 on Friday. - Edge Stock Ratings: 1.06 Momentum score. CorVel Corp (NASDAQ:CRVL) - On Sept. 12, CorVel's Brandon T. O’Brien stepped down as CFO. The company's stock fell around 14% over the past month and has a 52-week low of $72.15. - RSI Value: 27.2 - CRVL Price Action: Shares of CorVel rose 0.6% to close at $73.83 on Friday. - Benzinga Pro’s charting tool helped identify the trend in CRVL stock. Harmony Biosciences Holdings Inc (NASDAQ:HRMY) - On Sept. 24, Harmony Biosciences Holdings released topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS). Fragile X syndrome is a rare genetic disorder that is the leading known cause of both inherited intellectual disability and autism spectrum disorder. "We have a late-stage, catalyst-rich pipeline with multiple Phase 3 programs in the clinic and continue to be on track to initiate our Phase 3 trials for pitolisant HD in narcolepsy and idiopathic hypersomnia in the fourth quarter of this year. Harmony's unique profile as a profitable self-funding biotech company with strong cash-generation positions us well to drive future growth," said Jeffrey Dayno, President and CEO of Harmony Biosciences. The company's stock fell around 24% over the past month and has a 52-week low of $26.26. - RSI Value: 28.9 - HRMY Price Action: Shares of Harmony Biosciences gained 2% to close at $27.28 on Friday. - Benzinga Pro’s signals feature notified of a potential breakout in HRMY shares. Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare. Read This Next: Photo via Shutterstock © 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Three healthcare sector equities have been identified as technically oversold, with Relative Strength Index (RSI) values below the 30 threshold, yet their underlying catalysts present distinct risk profiles. MoonLake Immunotherapeutics (MLTX) exhibits the most extreme case, with an RSI of 21.5 following an 86% stock price collapse over the past month, triggered by its Phase 3 VELA trial results. Despite this, the stock recently rebounded 13% to $8.43, indicating potential speculative interest, though its low momentum score of 1.06 suggests caution. CorVel Corp (CRVL) entered oversold territory with an RSI of 27.2 after a more moderate 14% monthly decline, which coincided with the resignation of its CFO, introducing a management and governance concern. Harmony Biosciences (HRMY), with an RSI of 28.9, saw its stock fall 24% after releasing Phase 3 topline results. However, this negative market reaction is juxtaposed with bullish forward guidance from its CEO, who highlighted a 'catalyst-rich pipeline,' a profitable self-funding model, and strong cash generation, creating a potential disconnect between recent performance and the company's stated outlook.

Key Decisions for Investors

• Investors should differentiate between the technical oversold signals and the fundamental drivers, as the clinical trial disappointments at MLTX and HRMY present different risks than the governance uncertainty at CRVL.
• For MoonLake (MLTX), the deeply oversold RSI and subsequent 13% rebound may attract high-risk momentum traders, but the 86% drop on clinical data represents a significant fundamental impairment that warrants extreme caution.
• The CFO departure at CorVel (CRVL) is a red flag that requires further due diligence; the technical oversold signal should be secondary to understanding the potential impact on financial reporting and corporate strategy.
• Harmony Biosciences (HRMY) presents a potential value opportunity if the CEO's positive guidance on its pipeline and profitability proves more indicative of future performance than the market's negative reaction to recent trial data; the 'potential breakout' signal warrants monitoring this name closely.